IntelliPharmaCeutics' Manufacturing Facility Passes FDA cGMP and Pre-Approval Inspection

TORONTO, Nov. 15, 2011 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development, and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that its Toronto-based oral solid dosage forms manufacturing facility has completed a cGMP and pre-approval inspection process by the U.S. Food and Drug Administration ("FDA") and has been granted "acceptable" status under the Agency's strict regulatory guidelines. Intellipharmaceutics' Toronto manufacturing facility was previously inspected and approved by the Canadian regulatory authorities, Health Canada. Intellipharmaceutics currently has six Abbreviated New Drug Applications ("ANDAs") being reviewed by the FDA for the purpose of achieving regulatory approval.